Indoleamine 2,3-dioxygenase activity and l-tryptophan transport in human breast cancer cells  by Travers, M.T. et al.
www.bba-direct.com
Biochimica et Biophysica Acta 1661 (2004) 106–112Indoleamine 2,3-dioxygenase activity and L-tryptophan transport
in human breast cancer cells
M.T. Travers, I.F. Gow, M.C. Barber, J. Thomson, D.B. Shennan*
Hannah Research Institute, Ayr, Scotland KA6 5HL, UKReceived 14 October 2003; received in revised form 4 December 2003; accepted 4 December 2003Abstract
The activity and expression of indoleamine 2,3-dioxygenase together with L-tryptophan transport has been examined in cultured human
breast cancer cells. MDA-MB-231 but not MCF-7 cells expressed mRNA for indoleamine 2,3-dioxygenase. Kynurenine production by
MDA-MB-231 cells, which was taken as a measure of enzyme activity, was markedly stimulated by interferon-g (1000 units/ml).
Accordingly, L-tryptophan utilization by MDA-MB-231 cells was enhanced by interferon-g. 1-Methyl-DL-tryptophan (1 mM) inhibited
interferon-g induced kynurenine production by MBA-MB-231 cells. Kynurenine production by MCF-7 cells remained at basal levels when
cultured in the presence of interferon-g. L-Tryptophan transport into MDA-MB-231 cells was via a Na+-independent, BCH-sensitive
pathway. It appears that system L (LAT1/CD98) may be the only pathway for L-tryptophan transport into these cells. 1-Methyl-D,L-tryptophan
trans-stimulated L-tryptophan efflux from MDA-MB-231 cells and thus appears to be a transported substrate of system L. The results suggest
that system L plays an important role in providing indoleamine-2,3-dioxygenase with its main substrate, L-tryptophan, and suggest a
mechanism by which estrogen receptor-negative breast cancer cells may evade the attention of the immune system.
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Indoleamine 2,3-dioxygenase is a cytoplasmic, heme-
containing enzyme which catalyses the oxidative cleavage
of the indole moiety of a number of substituted and
unsubstituted indoleamines. In mammals, it catalyses the
initial step in the metabolism of L-tryptophan along the
kynurenine pathway [1]. Indoleamine 2,3-dioxygenase is
expressed in a number of tissues including the lung,
intestine, placenta and stomach [2]. Other features of the
enzyme include stimulation of activity by interferon-g [3]
and inhibition by 1-methyl-tryptophan [4].
Although the properties of indoleamine 2,3-dioxygenase
have been thoroughly studied its precise physiological roles
are only just being elucidated. A major advance is the
finding that indoleamine 2,3-dioxygenase is involved in
protecting the immunologically foreign conceptus from the
maternal immune system [5]. It is envisaged that placental0005-2736/$ - see front matter D 2004 Elsevier B.V All rights reserved.
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maternal T lymphocytes at the maternal–fetal interface by
lowering the local L-tryptophan concentration. This has
been termed as immunosuppression by starvation [6]. On
the other hand, it has been suggested that tryptophan
catabolites produced by indoleamine 2,3-dioxygenase may
be involved in immunoregulation by inhibiting T lympho-
cyte proliferation [7–9].
Indoleamine 2,3-dioxygenase is also believed to be
involved in regulating tumour growth [3]. A role for the
enzyme as an anti-tumour agent has focussed primarily on
the possibility that indoleamine 2,3-dioxygenase inhibits
tumour growth as a consequence of depriving cells of the
essential amino acid L-tryptophan. However, Mellor et al.
[10] have recently proposed that tumour cells may utilize
indoleamine 2,3-dioxygenase to protect themselves from the
immune system in a manner analogous to that found in the
fetal-placental unit (i.e. immunosuppression by starvation)
as described above. In support of this notion is the report
that 1-methyl-tryptophan, administered in vivo, resulted in
the delay of Lewis lung carcinoma tumour growth in
syngeneic mice [11].
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amine 2,3-dioxygenase in breast cancer pathology, we have
investigated the activity and expression of the enzyme in
two human breast cancer cell lines. We have studied
indoleamine 2,3-dioxygenase in MDA-MB-231 and
MCF-7 cells which are, respectively, estrogen receptor-
negative and -positive cells. We have also examined the
pathways available for the transport of L-tryptophan in
human breast cancer cells as the provision of substrate
may be an important factor in the regulation of indoleamine
2,3-dioxygenase activity [12].2. Methods
2.1. Culture of MDA-MB-231 and MCF-7 cells
MDA-MB-231 and MCF-7 cells were cultured in Dul-
becco’s modified Eagle medium (DMEM) supplemented
with L-glutamine (2 mM), heat-inactivated fetal bovine
serum (10%), penicillin (50 IU/ml) and streptomycin (50
Ag/ml). Both cell lines were cultured at 37 jC in a gas
phase of air with 5% CO2. Cells were cultured in 75 cm
2
flasks containing 12 ml of culture medium for 4–5 days
until they had reached approximately 90% confluency. The
cells were then cultured for a further 20 or 48 h in the
absence or presence of interferon-g. For transport studies,
cells were seeded in 35 mm culture wells containing 2 ml
of culture medium at a density of 0.3–1106 cells per
well and were used 24–48 h later when they had reached
60–90% confluency.
2.2. RNA isolation and RT-PCR
Total cellular RNA was isolated from breast cancer
cells and human placental tissue using Triazol reagent
(InVitrogen). Maternal decidue was removed from the
placental tissue prior to RNA extraction. RNA was sus-
pended in water and the concentration determined by the
A260, where one unit of absorbance measured at 260 nm
corresponds to 40 Ag of RNA. The integrity of the RNA
was checked by electrophoresis in a 1.2% agarose gel
containing 2.2 M formaldehyde and 0.5 Ag/ml of ethidium
bromide [13].
PCR primers for indoleamine 2,3-dioxygenase and CD98
were designed from the sequences available in GenBank
(accession numbers X17668 and AH001404 for indole-
amine 2,3-dioxygenase and CD98 (4F2hc), respectively).
Primer pairs were designed to different exons to prevent the
amplification of any contaminating DNA. The primer pairs
used in the subsequent PCRs were as follows: indoleamine
2,3-dioxygenase, forward 5V AACAGCGCCTTTAG-
CAAAGTGTCCCGTTCTTG 3V, and reverse 5V AGC-
GCCTTGCACGTCTAGTTCTGGGATGC 3V; CD98,
forward 5VCTGGCGGGTCTGAAGGGGCGTCTCGAT-
TAC 3V and reverse 5VTCACCCCCGTAGTTGGGAG-TAAGGTCCAGA 3V. The expected sizes of the PCR
products were 376 bp for indoleamine 2,3-dioxygenase
and 224 bp for CD98.
cDNA was prepared from 1 Ag samples of total RNA
using M-MLV reverse transcriptase (Promega) and random
hexamers (Pharmacia). The cDNA (0.04 Ag equivalent to
RNA) was PCR amplified using Taq polymerase (Thermo-
Start Master Mix, ABgene) and 0.2 AM of each of the
appropriate primer pair, in a total volume of 25 Al.
Samples were denatured initially at 94 jC for 5 min,
followed by 35 cycles of 92 jC for 30 s, 59.8 jC (for
indoleamine 2,3-dioxygenase) or 60.3 jC (for CD98) for
30 s and 72 jC for 30 s with a final 5 min extension at 72
jC. Aliquots (5 Al) of the PCRs were then resolved on a
1% agarose/TBE gel and the products visualised by
ethidium bromide staining. The authenticity of the PCR
products were verified by digestion with specific restriction
endonucleases.
2.3. Measurement of indoleamine 2,3-dioxygenase activity
Indoleamine 2,3-dioxygenase activity was measured
using the method of Takikawa et al. [14] as modified by
Kudo and Boyd [15]. MDA-MB-231 and MCF-7 cells
were harvested by trypsin digestion. The cells were
washed twice and resuspended in 1 ml of a buffer con-
taining (mM) 130 NaCl and 50 Tris-MOPS, pH 7.4. The
cells were disrupted by sonification for 30 s on ice at a
power of 100 W. The homogenate was centrifuged at
12,000 g for 5 min at room temperature. Samples of
the supernatant were taken to determine the protein content
by the Lowry assay using bovine serum albumin as
standard. Following this, 0.4 ml of the supernatant was
added to an equal volume of a solution containing 1 mM
L-tryptophan, 20 AM methylene blue, 40 mM ascorbic
acid, catalase (200 units/ml) and 100 mM potassium
phosphate buffer, pH 6.5. Both the enzyme suspension
and incubation buffer were pre-heated to 37 jC before
mixing. The mixture was incubated for a further 30 min at
37 jC. The reaction was stopped by adding 0.2 ml of 30%
(w/v) trichloroacetic acid. The mixture was incubated at 50
jC for 30 min to hydrolyse N-formylkynurenine produced
by indoleamine 2,3-dioxygenase to kynurenine. The reac-
tion mixture was then centrifuged at 12,000 g at room
temperature to remove sediment. Supernatant (0.8 ml) was
added to 0.8 ml of 1% (w/v) p-dimethylaminobenzalde-
hyde in acetic acid. The absorbance at 480 nm was
determined.
2.4. Measurement of L-tryptophan by HPLC
Samples of culture medium either unconditioned or
conditioned by culture with MDA-MB-231 and MCF-7
cells were deproteinised as follows: each sample (900 Al)
was added to a mixture of 15% perchloric acid/2 mM
cysteine (100 Al), vortexed and allowed to stand on ice for
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fuged for 5 min at 20,000 g at room temperature. The
supernatants were removed and stored at 4 jC prior to
assay. Standards containing 5 or 50 AM L-tryptophan and
1.5% perchloric acid/0.2 mM cysteine in double-distilled
water were injected at the start, middle and end of each
assay. The HPLC system was isocratic, using a mobile
phase of 2.7% acetonitrile, 97.3% water v/v and 15 mM
KH2PO4; delivered at a rate of 1 ml/min. For analysis, 20
Al of standard or sample were injected. Separation was
achieved using an APEX 25 cm reverse-phase column (5
Am diameter packing; Jones Chromatography). The detec-
tor was a Kratos Spectroflow 98 fluorimeter, with excita-
tion at 230 nm and emission >370 nm; tryptophan was
measured at 0.2 fluorescence units full-scale. Chromato-
grams were recorded on a Shimadzu C-R6A Chromatopac
integrator, with peak height being used to calculate con-
centrations. The mean coefficients of variation were 1.1%
(intra-assay; n = 6) and 10.4% (inter-assay; n = 7).
2.5. Measurement of L-tryptophan uptake
The unidirectional uptake of L-tryptophan into MDA-
MB-231 cells was measured according to the method of
Shennan et al. [16] using L-[5-3H]tryptophan (Amersham
International, PLC; specific activity 33.0 Ci/mmol) as
tracer. The culture medium was removed and the cells
were washed three times with 3 ml of a buffer containing
(mM) 0.01 L-tryptophan, 135 NaCl or choline-Cl, 5 KCl, 2
CaCl2, 1 MgSO4, 10 glucose and 10 Tris-MOPS, pH 7.4.
The cells were then preincubated for 5 min at 37 jC in 3
ml of an appropriate buffer (see figure legends for details).
L-Tryptophan influx experiments were initiated by aspirat-
ing the preincubation buffer and replacing it with 1 ml of a
buffer containing (mM) 0.01 L-tryptophan, 135 NaCl or
choline-Cl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose and 10
Tris-MOPS, pH 7.4 plus 1 ACi/ml of [3H]L-tryptophan and
0.4 ACi/ml of [14C]sucrose together with other additions
such as unlabelled amino acids. The specific activity of the
isotopes in the incubation buffer was determined by
counting the radioactivity associated with 10 Al of buffer:
the samples were prepared for counting by adding 0.5 ml
of distilled water and 10 ml of UltimaGold liquid scintil-
lation cocktail. After 30 s, the incubation buffer was
removed and the cells were washed four times with 3 ml
of an ice-cold buffer containing (in mM): 135 choline-Cl,
5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose and 10 Tris-MOPS,
pH 7.4. The cells were lysed by incubating in 1 ml of
distilled water for at least 3 h during which time the lysate
was frequently agitated. A sample of the lysate (0.5 ml)
was added to an equal volume of 10% TCA (w/v) and
centrifuged at 12,000 g for 10 min, 0.5 ml of the
supernatant was prepared for counting by adding 10 ml
of UltimaGold liquid scintillation fluid. Samples of the
lysate (0.1 ml) were taken to determine the protein content




where [L-tryptophan]c is the amount of L-tryptophan in the
cells (pmol/mg protein), [L-tryptophan]t is the total amount
of L-tryptophan in the lysate (pmol), [L-trytophan]m is the
amount of L-tryptophan in the medium (pmol), F is the
ratio of radiolabelled sucrose in the lysate to that in the
incubation medium and P is the amount of protein in the
lysate (mg).
2.6. Measurement of tryptophan efflux
The efflux of L-tryptophan from MDA-MB-231 cells was
assayed using L-[5-3H]tryptophan as tracer. After removing
the culture medium, the cells were washed three times with
2 ml of a solution containing (mM) 135 choline-Cl, 5 KCl, 2
CaCl2, 1 MgSO4, 10 glucose and 10 Tris-MOPS, pH 7.4.
The cells were loaded with radiolabelled L-tryptophan over
a period of 10 min at 37 jC by incubating in 2 ml of a buffer
similar in composition to that just described except that it
also contained 1 ACi/ml of [3H]L-tryptophan. After the
loading period, the cells were washed four times in rapid
succession with a radioactive-free buffer similar in compo-
sition to that described above. The efflux of [3H]L-trypto-
phan from the cells was measured by the sequential addition
and removal of 2 ml of buffer (see figure legends for precise
details) at 1-min intervals. At the end of the wash-out
period, cells were incubated in 2 ml of 10% TCA for at
least 3 h. Following this, the samples were centrifuged at
12,000 g for 5 min after which 1 ml of the supernatant
was added to 10 ml of UltimaGold liquid scintillation fluid.
The fractional release for each collection period was calcu-
lated according to Eq. (2):
Fractional efflux ¼ DX=ðDtXtÞ ð2Þ
where DX is the amount of radiolabelled L-tryptophan
released from the cells in the time interval Dt and Xt is the
amount of isotope in the cells at the start of each collection
period.3. Results
3.1. Indoleamine 2,3-dioxygenase activity
Fig. 1 illustrates the activity of indoleamine 2,3-diox-
ygenase in MDA-MB-231 and MCF-7 cells which had
been cultured in the absence and presence of interferon-g
(1000 units/ml) for 48 h. Kynurenine production was
taken as a measure of enzyme activity. It is evident that
indoleamine 2,3-dioxygenase activity was relatively low
Table 1
Effect of interferon-g on L-tryptophan concentrations in medium con-
ditioned following culture of MDA-MB-231 and MCF-7 cells
L-Tryptophan concentration (AM)
Non-conditioned  Interferon-g + Interferon-g
MDA-MB-231 66.2F 2.7 53.1F1.7* 8.0F 6.8**yy
MCF-7 72.2F 2.7 56.8F 2.5* 41.2F 1.8*y
Culture conditions were the same as those described in Fig. 1. Each value is
the meanF S.E. of three experiments.
yP< 0.05 vs.Interferon-c
yyP< 0.02 vs.Interferon-c
Fig 1. Indoleamine 2,3-dioxygenase activity in MDA-MB-231 and MCF-7
cells cultured in the presence and absence of interferon-g (1000 units/ml)
for 48 h (values shown are meanF S.E., n= 9 and 4, respectively, when
MDA-MB-231 and MCF-7 cells were used).
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the absence of interferon-g. However, interferon-g mark-
edly stimulated enzyme activity in MDA-MB-231 cells.
Thus, kynurenine production by indoleamine 2,3-dioxyge-
nase from cells which had been cultured in the absence
and presence of the cytokine was, respectively, 0.12F 0.05
and 6.22F 0.88 nmol/min/mg protein (F S.E., n = 9,
P < 0.001). In contrast, interferon-g failed to significantly
stimulate indoleamine 2,3-dioxygenase activity in MCF-7
cells: the activity of the enzyme from cells which had
been cultured with and without interferon-g was, respec-
tively, 0.25F 0.04 and 0.20F 0.16 nmol/min/mg protein
(S.E., n= 4). The stimulation of indoleamine 2,3-dioxy-
genase activity in MDA-MB-231 cells by interferon-g
was time-dependent. Thus, the cytokine-induced produc-
tion of kynurenine by MDA-MB-231 cells cultured for
20 h was significantly lower (P < 0.001) than that found
after a 48 h incubation (2.09F 0.22 v 6.11F 0.84 nmol/
min/mg protein). We also found that 1-Methyl-DL-trypto-
phan (1 mM), a competitive inhibitor of indoleamine 2,3-
dioxygenase [4], reduced the interferon-g-induced produc-
tion of kynurenine by MDA-MB-231 cells by 46.7%:
kynurenine formation in the absence and presence of 1-
methyl-DL-tryptophan was, respectively 7.83F 1.63 and
4.17F 1.01 nmol/min/mg protein (F S.E., n = 3, P < 0.05).
1-Methyl-DL-tryptophan had no effect on kynurenine pro-
duction by cells which had been cultured in the absence of
interferon-g.
The concentration of L-tryptophan in the conditioned
medium following culture of MDA-MB-231 and MCF-7cells was measured (Table 1). In this set of experiments,
cells were cultured with or without interferon-g (1000 units/
ml) for 48 h. It is evident that inclusion of interferon-g in the
culture medium markedly stimulated the degradation of L-
tryptophan by MDA-MB-231 cells and to a lesser extent by
MCF-7 cells.
3.2. Expression of indoleamine 2,3-dioxygenase mRNA
We subjected total RNA isolated from MDA-MB-231
and MCF-7 cells (which had been cultured in the absence
of interferon-g) to RT-PCR to test for the expression of
indoleamine 2,3-dioxygenase mRNA. Human placental
tissue was used as a positive control since the presence
of indoleamine 2,3-dioxygenase mRNA in human placen-
tal trophoblast has been reported [17]. CD98 expression
was also used as a positive control given that it is
expressed in MDA-MB-231 cells, MCF-7 cells and human
placental tissue [16]. In accordance with previous results,
we found a product for the expected size for CD98 in all
three cell/tissue types. A product for the expected size for
indoleamine 2,3-dioxygenase mRNA was found in placen-
tal tissue and MDA-MB-231 cells but not MCF-7 cells
(Fig. 2).
3.3. L-Tryptophan transport by MDA-MB-231 cells
Indoleamine 2,3-dioxygenase is a tryptophan cataboliz-
ing enzyme, therefore, the provision of the essential amino
acid could be an important point in the regulation of
enzyme activity [12]. In view of this, we investigated the
transport (i.e. influx and efflux) of L-tryptophan by MDA-
MB-231 cells. Fig. 3 shows that L-tryptophan uptake into
MDA-MB-231 cells was not affected by replacing extra-
cellular Na+ with choline. Tryptophan uptake in the
presence and absence of extracellular Na+ was, respective-
ly, 1.17F 0.05 and 1.29F 0.05 nmol/30 s/mg protein. Fig.
3 also shows that L-tryptophan influx was inhibited by
BCH (2-amino-2-norbornane-carboxylic acid), a compound
regarded to be a relatively specific inhibitor of system L.
Replacing Na+ with choline did not affect the inhibition of
L-tryptophan uptake by BCH (Fig. 3). Thus, BCH inhibited
L-tryptophan uptake by 91.3F 3.6% and 94.2F 2.0%,
Fig. 2. Indoleamine 2,3-dioxygenase and CD98 RT-PCR products from
human placenta, MCF-7 cells and MDA-MB-231 cells. The control track
represents PCR in the absence of cDNA. Samples are representative of
three independent RNA preparations for each cell/tissue type.
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Na+.
We examined the properties of L-tryptophan efflux from
MDA-MB-231 cells incubated under Na+-free conditions.
BCH stimulated L-tryptophan efflux from MDA-MB-231
cells (Fig. 4A). Thus, BCH at a concentration of 1 mMFig. 3. The effect of BCH on L-tryptophan uptake by MDA-MB-231 cells
in the presence and absence of extracellular Na+. The incubation medium
contained (in mM): 0.01 L-tryptophan, 135 NaCl or choline-Cl, 5 KCl, 2
CaCl2, 1 MgSO4, 10 glucose and 10 Tris-MOPS, pH 7.4, 1 ACi/ml [3H]L-
tryptophan and 0.4 ACi/ml [14C]sucroseF 10 BCH. Uptake was measured
at 37 jC after 30 s of incubation. The results are the meanF S.E. of three
experiments.increased L-tryptophan efflux (basal-to-peak) from
0.032F 0.005 min 1 to 0.523F 0.050 min 1 (S.E., n = 3,
P < 0.01). We also found that 1-methyl-D,L-tryptophan stim-
ulated L-tryptophan efflux from MDA-MB-231 cells in a
dose-dependent manner (Fig. 4B). 1-Methyl-D,L-tryptophan
at a concentration of 0.01, 0.1 and 1.0 mM, respectively,
stimulated L-tryptophan efflux (basal-to-peak) by 327.8F
19.2% ( P < 0.01), 624.4 F 38.6% ( P < 0.01) and
958.9F 71.4% (P < 0.001). Notably, BCH (1 mM) did notFig. 4. The effect of (A) BCH and (B) 1-methyl-DL-tryptophan (B) on L-
tryptophan efflux from MDA-MB-231 cells. The incubation medium
contained (in mM): 135 choline-Cl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose
and 10 Tris-MOPS, pH 7.4. BCH when required was used at a
concentration of 1 mM. 1-Methyl-DL-tryptophan, when required was used
at a concentration of 0.001 mM (z), 0.01 mM (E), 0.1 mM (.) and 1 mM
(n). Each point is the meanF S.E. of three experiments.
Fig. 5. The effect of BCH in the presence of 1-methyl-DL-tryptophan on L-
tryptophan efflux from MDA-MB-231 cells. The incubation medium
contained (in mM): 135 choline-Cl, 5 KCl, 2 CaCl2, 1 MgSO4, 10 glucose,
1 1-methyl-DL-tryptophan and 10 Tris-MOPS, pH 7.4F 1 BCH. Each point
is the meanF S.E. of six experiments.
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1-methyl-DL-tryptophan (Fig. 5).4. Discussion
4.1. Activity and expression of indoleamine 2,3-dioxygenase
On the basis that indoleamine 2,3-dioxygenase appears to
play a central role in protecting the fetus from a maternal
immune response, Mellor et al. [10] suggested that the
catabolism of L-tryptophan by indoleamine 2,3-dioxygenase
may also help tumour cells escape the attention of the
immune system. This prompted us to investigate the poten-
tial role of indoleamine 2,3-dioxygenase in breast cancer
pathology. Thus, we have investigated the expression and
activity of indoleamine 2,3-dioxygenase in two human
breast cancer cell lines, namely MDA-MB-231 (estrogen
receptor-negative) and MCF-7 (estrogen receptor-positive).
The results show that MDA-MB-231 cells express indole-
amine 2,3-dioxygenase at the functional and molecular
level. Thus, MDA-MB-231 cells express mRNA for the
enzyme and are capable of metabolizing L-tryptophan via
the kynurenine pathway in a time-dependent fashion when
cultured in the presence of interferon-g. Accordingly, we
found that interferon-g increased L-tryptophan utilization by
MDA-MB-231 cells. Another important feature is that
interferon-g-induced kynurenine production by MDA-MB-
231 was sensitive to 1-methyl-DL-tryptophan. Indoleamine
2,3-dioxygenase from the rabbit intestine and human pla-
centa is competitively inhibited by 1-methyl-DL-tryptophan
[4,12]. Indeed, this compound was used by Munn et al. [5]to inhibit indoleamine 2,3-dioxygenase in pregnant mice
which, in turn, resulted in fetal rejection.
In contrast to MDA-MB-231 cells, we found that MCF-7
cells did not express indoleamine 2,3-dioxygenase mRNA.
Moreover, in accordance with previous results [18], we
found that basal kynurenine production in MCF-7 cells
was low and could not be induced by interferon-g. In view
of this, it is tempting to suggest that there may be a
difference between estrogen receptor-positive and -negative
breast cancer cells with respect to the expression of indole-
amine 2,3-dioxygenase. We did find, however, that interfer-
on-g stimulated L-tryptophan utilization by MCF-7 cells,
albeit to a smaller extent. It is apparent that the interferon-g-
induced catabolism of L-tryptophan by MCF-7 cells must
occur via another, as yet unidentified, pathway.
The finding that MDA-MB-231 cells express indoleamine
2,3-dioxygenase suggest that estrogen receptor-negative
breast cancer cells may express the enzyme in vivo. There-
fore, this study forms the basis for future work on the
potential role of indoleamine 2,3-dioxygenase in human
breast cancer pathology. A major focus should be identifying
the presence of the enzyme in primary breast cancer cells and
examining the relationship between its expression and hor-
mone-receptor status. Based on our findings with cell lines,
there is the distinct possibility that Munn et al.’s hypothesis of
immunosuppression by starvation could be applicable to
estrogen receptor-negative breast cancer cells. It is envisaged
that breast cancer cells could utilize indoleamine 2,3-dioxy-
genase to reduce L-tryptophan in their immediate environ-
ment and consequently inhibit T cell proliferation.
Alternatively, production of L-tryptophan metabolites by
indoleamine 2,3-dioxygenase could possibly result in T cell
apoptosis [9]. Whilst this report was being prepared, Uytten-
hove et al. [19] reported that indoleamine 2,3-dioxygenase
protein could be detected in a variety of human tumours
including breast carcinomas. However, whilst indoleamine
2,3-dioxygenase was present in all prostate, colorectal, pan-
creatic and cervical tumours analysed, only 30% of breast
tumours exhibited the enzyme. It is possible, as suggested
above, that the expression of the enzyme in vivo may be
related to the hormone-receptor status of the tumour which
was not reported by Uyttenhove et al. [19].
4.2. Transport of L-tryptophan by MDA-MB-231 cells
L-Tryptophan transport, via system L, in human placental
tissue has been shown to play an important role in the
regulation of indoleamine 2,3-dioxygenase [12]. In view of
this, we examined L-tryptophan transport in MDA-MB-231
cells because an understanding of the transport mechanism
could be important in relation to developing potential
therapeutic strategies aimed at inhibiting indoleamine 2,3-
dioxygenase activity in breast cancer cells. The results show
that L-tryptophan, the major substrate of indoleamine 2,3-
dioxygenase, gains access to MDA-MB-231 cells via a
BCH-sensitive, Na+-independent pathway. Therefore, the
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neutral amino acid transport mechanism, being the major
conduit for L-tryptophan entry into MDA-MB-231 cells.
System L is not a single transporter and recent studies have
shown that there are at least two molecular correlates of
system L [20–24]. Two proteins termed LAT1 and LAT2
induce system L-like activity when co-expressed with
CD98. Thus, the transport protein is a heterodimer consist-
ing of a light chain (LAT1 or LAT2) and a heavy chain
(CD98). In this connection, we have recently shown that
MDA-MB-231 cells express LAT1 (but not LAT2) and
CD98 [16]. Indeed, from the present results, it appears that
system L (LAT1/CD98) may be the only pathway available
for L-tryptophan transport into MDA-MB-231 cells under
these conditions. This places system L in a potentially
important position as a therapeutic target. We have also
shown that 1-methyl-D,L-tryptophan, a competitive inhibitor
of indoleamine 2,3-dioxygenase, was able to trans-stimulate
L-tryptophan efflux from MDA-MB-231 cells. Importantly,
BCH failed to trans-accelerate L-tryptophan efflux in the
presence of extracellular 1-methyl-D,L-tryptophan suggest-
ing that both compounds are acting at a single locus. This
suggests that 1-methyl-D,L-tryptophan is acting to stimulate
L-tryptophan efflux via system L (LAT1/CD98). Moreover,
the finding that 1-methyl-D,L-tryptophan trans-stimulates L-
tryptophan efflux from MDA-MB-231 cells suggest that 1-
methyl-D,L-tryptophan is a transported substrate of system
L. This finding may assume more importance in light of the
suggestion that 1-methyl-tryptophan could possibly be used
to enhance anti-tumour immunity in cancer patients [10,19].Acknowledgements
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